Neuphoria Therapeutics Inc.

Listed Company

NEUPCIK 0001191070NasdaqNon-AcceleratedSmaller ReportingEmerging GrowthPharmaceutical PreparationsC3FY ends Jun 30

Period

FY 2025

Revenue

$15.65M

Net Income

$-400.0K

Total Assets

$28.59M

Equity

$19.00M

Shares Out

5.39M

Op. Cash Flow

$100.0K

Business

Neuphoria Therapeutics Inc. is a clinical-stage biotechnology company developing therapies for neuropsychiatric and CNS disorders. Its main product candidate is BNC210, an oral selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor for acute treatment of social anxiety disorder and chronic treatment of post-traumatic stress disorder, and it advances α7 PAMs, Kv3.1/3.2 activators and legacy oncology assets. The company operates through clinical development, discovery and partnership programs, including a strategic collaboration with Merck and out-licensing of oncology assets. Neuphoria conducts clinical trials across the United States, the United Kingdom and other sites, intends to commercialize in the U.S., pursues ex-U.S. partnerships, and relies on third-party manufacturing and distribution channels.

Summary from filing dated 2025-09-29

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-06-30	FY 2024 2024-06-30	FY 2023 2023-06-30
License revenue	16	—	—
Research and development	9	9	13
General and administrative	8	8	9
Total operating expenses	17	18	22
Loss from operations	−1	−18	−22
Interest income, net	166,498	220,097	323,158
Loss on foreign currency transactions	−414,996	−209,842	308,852
Research and development incentive award	299,905	95,215	422,742
Gain on fair value adjustments	239,686	2	−592,627
Total other income	291,093	2	462,125
Loss before income tax benefit	−837,998	−16	−22
Income tax benefit	468,366	87,320	139,174
Net loss	−400,000	−16	−21
Unrealized gain on foreign currency translation	168,529	45,188	−1
Total other comprehensive income	168,529	45,188	−1
Total comprehensive loss	−201,103	−15	−22
Net loss per share - basic	−0.23	−18.62	−0.02
Net loss per share - diluted	−0.23	−18.62	−0.02
Weighted-average common shares outstanding - basic	2	832,225	1,469
Weighted-average common shares outstanding - diluted	2	832,225	1,469

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-06-30	FY 2024 2024-06-30	FY 2023 2023-06-30	FY 2022 2022-06-30
Cash and cash equivalents	14	13	12	—
Accounts receivable, non-trade	11,948	126,884	426,087	—
Restricted cash	77,945	—	—	—
Prepaid expenses	740,193	458,765	797,478	—
Total current assets	15	13	13	—
Property and equipment, net	2,771	1,994	2,522	—
Intangible assets, net	5	5	6	—
Operating lease right-of-use assets	102,612	216,975	330,478	—
Restricted cash	—	78,826	78,897	—
Goodwill	9	9	9	9
Total assets	29	28	29	—
Accounts payable	1	2	1	—
Accrued expenses and other current liabilities	3	1	1	—
Operating lease liability	116,314	121,990	113,930	—
Total current liabilities	4	4	3	—
Operating lease liability, net of current portion	—	117,628	239,835	—
Contingent consideration	1	587,762	2	—
Deferred tax liability	495,113	963,540	1	—
Accompanying warrant liability	4	5	—	—
Other non-current liabilities	—	2,886	14,850	—
Total liabilities	10	10	7	—
Commitments and contingencies	—	—	—	—
Common stock, $0.00001 par value, 1,978,460 and 1,103,954 shares issued and outstanding at June 30, 2025 and 2024, respectively	19	11	—	—
Additional paid in capital, net of subscription receivable	200	198	188	—
Accumulated other comprehensive loss, net of tax	−3	−3	−3	—
Accumulated deficit	−178	−178	−162	—
Total shareholders equity	19	17	22	39
Total liabilities and shareholders equity	29	28	29	—

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-06-30	FY 2024 2024-06-30	FY 2023 2023-06-30
Share-based compensation	163,772	814,808	1
Depreciation and amortization expense	662,890	662,991	663,192
Non-cash rent expense	114,363	113,503	115,123
Change in fair value of accompanying warrant liability	−956,340	−338,983	—
Change in fair value of contingent consideration	716,654	−2	592,627
Effect of foreign currency remeasurement	242,348	−27,350	−556,782
Accounts receivable, non-trade	114,936	299,203	4
Prepaid expenses	−453,058	338,713	—
Accounts payable	−917,663	804,371	374,176
Accrued expenses and other current liabilities	1	277,854	138,079
Operating lease liabilities	−123,304	−114,147	−107,808
Deferred tax liability	−468,427	−139,173	−139,173
Contingent consideration	−133,080	—	—
Other non-current liabilities	−2,886	−11,964	8,041
Net cash provided by (used in) operating activities	100,000	−15	−15
Proceeds from the sale of equity, net of subscriptions receivable and issuance costs	2	10	—
Proceeds from the sale of accompanying warrant	—	5	—
Net cash provided by financing activities	2	15	4
Effect of exchange rate on changes on cash, cash equivalents, and restricted cash	−3,750	76,974	−243,822
Net increase in cash, cash equivalents, and restricted cash	2	504,991	—
Cash paid for interest expense	17,433	31,516	—
Cash paid for income tax expense	—	51,853	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro